Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:neurodegenerative_diseases
|
| gptkbp:affects |
motor neurons
|
| gptkbp:awareness_organization |
gptkb:Motor_Neurone_Disease_Association_(MNDA)
gptkb:ALS_Association |
| gptkbp:cause |
progressive degeneration
|
| gptkbp:condition |
gptkb:frontotemporal_dementia
pain spasticity |
| gptkbp:diagnosis |
clinical examination
nerve conduction studies electromyography (EMG) variable progression average survival 3-5 years |
| gptkbp:epidemiology |
more common in men
affects 2 per 100,000 people peak onset age 55-75 |
| gptkbp:famous_person |
gptkb:Terry_Pratchett
gptkb:Stephen_Hawking gptkb:Morrissey gptkb:Lou_Gehrig gptkb:David_Niven |
| gptkbp:genetic_studies |
gptkb:TARDBP
gptkb:C9orf72 gptkb:SOD1 FUS |
| gptkbp:historical_figures |
awareness campaigns
advocacy for research funding |
| https://www.w3.org/2000/01/rdf-schema#label |
Motor Neurone Disease
|
| gptkbp:medications |
gptkb:Edaravone
gptkb:Riluzole |
| gptkbp:public_awareness |
gptkb:June
|
| gptkbp:research |
environmental factors
genetic factors ongoing studies |
| gptkbp:symptoms |
difficulty speaking
respiratory problems muscle weakness difficulty swallowing muscle atrophy |
| gptkbp:treatment |
medications
physical therapy supportive care speech therapy |
| gptkbp:type_of |
Amyotrophic lateral sclerosis (ALS)
Bulbar onset ALS Primary lateral sclerosis (PLS) Progressive muscular atrophy (PMA) |
| gptkbp:bfsParent |
gptkb:Rob_Burrow
gptkb:Doddie_Edwards |
| gptkbp:bfsLayer |
5
|